Andrew Allen is the founder of Gritstone bio. Gritstone bio has raised $102M in total funding. Latest round: Series A. Based in San Francisco, United States.
Andrew Allen, M.D., Ph.D., is the co-founder, president, and CEO of Gritstone Oncology, focusing on developing personalized cancer immunotherapies. The company announced a Series A financing of $102 million to support the discovery and development of novel tumor-specific neo-antigen based immunotherapies, initially targeting lung cancer.
Full founder directory · Investor directory · Company funding database · Fundraising library